A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

ClinicalTrials.gov ID: NCT06220201

Public ClinicalTrials.gov record NCT06220201. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants With Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG).

Study identification

NCT ID: NCT06220201
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Enrollment: 120 participants

Conditions and interventions

Conditions

Interventions

CC-97540 Drug
Fludarabine Drug
Cyclophosphamide Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 60 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 27, 2024
Primary completion: Jul 14, 2027
Completion: Jul 14, 2027
Last update posted: Jun 30, 2026

2024 – 2027

United States locations

U.S. sites: 17
U.S. states: 14
U.S. cities: 16

Facility	City	State	ZIP	Site status
Local Institution - 0011	Birmingham	Alabama	35294	Active, not recruiting
University of California, Irvine	Irvine	California	92697	Recruiting
University of Colorado Anschutz Medical Campus	Aurora	Colorado	80045	Recruiting
Colorado Blood Cancer Institute	Denver	Colorado	80218	Recruiting
Yale-New Haven Hospital	North Haven	Connecticut	06473	Recruiting
University of Kansas Medical Center	Kansas City	Kansas	66160	Recruiting
Local Institution - 0039	New Orleans	Louisiana	70121	Withdrawn
Local Institution - 0005	Boston	Massachusetts	02114	Completed
Washington University School of Medicine	St Louis	Missouri	63110	Recruiting
Hackensack University Medical Center	Hackensack	New Jersey	07601	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
Neurological Institute of New York	New York	New York	10032	Recruiting
University of Cincinnati Medical Center	Cincinnati	Ohio	45219	Recruiting
Cleveland Clinic Mellen Center	Cleveland	Ohio	44195	Recruiting
Oregon Health and Science University	Portland	Oregon	97239	Recruiting
Swedish Medical Center	Seattle	Washington	98122	Recruiting
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06220201, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 30, 2026 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06220201 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →